10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2019 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 25, 2020) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Operating Activities: | |||
| Net income | $ 5,364 | 5,460 | 4,644 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 255 | 226 | 233 |
| Amortization expense | 1,149 | 1,203 | 1,053 |
| Stock-based compensation expense | 636 | 845 | 638 |
| Deferred income taxes | (2,098) | 289 | (82) |
| Net gains from equity securities | (1,241) | (115) | 0 |
| Up-front and milestone expense related to collaborative and other arrangements | 4,346 | 0 | 0 |
| In-process research and development impairment | 800 | 820 | 0 |
| Write-downs for slow moving and excess raw material and work in process inventory | 547 | 440 | 0 |
| Other | 184 | 171 | 304 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (218) | 480 | 754 |
| Inventories | (95) | (310) | (253) |
| Prepaid expenses and other | (307) | 903 | 358 |
| Accounts payable | (61) | (39) | (430) |
| Income taxes payable | 272 | (1,459) | 5,497 |
| Accrued liabilities | (389) | (514) | (818) |
| Net cash provided by operating activities | 9,144 | 8,400 | 11,898 |
| Investing Activities: | |||
| Purchases of marketable debt securities | (30,455) | (10,233) | (23,314) |
| Proceeds from sales of marketable debt securities | 7,523 | 1,522 | 10,440 |
| Proceeds from maturities of marketable debt securities | 22,398 | 24,336 | 7,821 |
| Up-front and milestone payments related to collaborative and other arrangements | (4,301) | 0 | 0 |
| Purchases of equity securities | (1,773) | (156) | 0 |
| Acquisitions, net of cash acquired | 0 | 0 | (10,426) |
| Capital expenditures | (825) | (924) | (590) |
| Other | (384) | (190) | 0 |
| Net cash (used in) provided by investing activities | (7,817) | 14,355 | (16,069) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 0 | 0 | 8,985 |
| Proceeds from issuances of common stock | 209 | 289 | 234 |
| Repurchases of common stock | (1,749) | (2,900) | (954) |
| Repayments of debt and other obligations | (2,750) | (6,250) | (1,811) |
| Payment of dividends | (3,222) | (2,971) | (2,731) |
| Other | (122) | (486) | (330) |
| Net cash (used in) provided by financing activities | (7,634) | (12,318) | 3,393 |
| Effect of exchange rate changes on cash and cash equivalents | (2) | (85) | 137 |
| Net change in cash and cash equivalents | (6,309) | 10,352 | (641) |
| Cash and cash equivalents at beginning of period | 17,940 | 7,588 | |
| Cash and cash equivalents at end of period | 11,631 | 17,940 | 7,588 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 982 | 1,070 | 1,038 |
| Income taxes paid | 1,793 | 3,198 | 3,342 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |